Sat.Dec 19, 2020 - Fri.Dec 25, 2020

article thumbnail

DNA analysis could pinpoint ‘long haulers’ among COVID-19 patients

Outsourcing Pharma

The analytical tool, developed via Bionano Genomics, maps structural variations in DNA that are known to cause disease and are tied to symptom severity.

141
141
article thumbnail

NHS leaders urge UK government to extend Brexit transition period

pharmaphorum

NHS leaders have written to the UK prime minister urging him to extend the Brexit transition period by a month to avoid plunging the healthcare service into chaos on 1 January. The letter, published today by the NHS Confederation – a membership organisation representing NHS leaders from all parts of the health service, outlines concerns about the impact a no-deal outcome will have on delivering care to patients amid winter pressures and a rapid rise in COVID-19 infections. “The failu

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

EU nod for first long-acting HIV injectable treatment

Pharma Times

Rekambys plus Vocabria authorised to treat HIV-1 infections in adults who are virologically suppressed

62
article thumbnail

Christmas 2020 Reflections

That Frugal Pharmacist

It’s Christmas Eve 2020. Wow, what a wild year it has been for us all. Socio-political unrest. A more tense than usual election. A global pandemic.

52
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

‘Explosion’ of health data fuels pharma advances: Linguamatics

Outsourcing Pharma

A leader from the IQVIA company explains how the boom in the volume and quality of data, and advanced analysis, can speed and streamline drug development.

110
110
article thumbnail

UK prepares for decision on AZ/Oxford vaccine as COVID cases soar

pharmaphorum

The UK’s COVID-19 vaccination programme could get a speed boost, with the country’s drugs regulator expected to make a decision on a shot from Oxford University/AstraZeneca in the next few days. If the vaccine becomes available the UK will be able to step up its vaccination programme as large swathes of the country face draconian “Tier 4” restrictions due to the emergence of as more infectious variant.

Vaccines 126

More Trending

article thumbnail

Botanical Solution Inc. (BSI) Secures $3.3 Million in Funding with Second Round Planned for Spring 2021

Pharma Mirror

Davis, CA: Botanical Solution Inc. (BSI), innovator of sustainable, highly consistent and cost effective Advanced Botanical Materials, has successfully secured $3.3 million in a seed round of funding, and is planning another round of funding for Spring 2021. The Spring 2021 Round of funding will boost BSI’s proven ability to discover and develop novel botanical products that are sustainable, highly consistent and cost effective.

52
article thumbnail

Ingredients, innovation and a need for speed: what’s in store for 2021

Outsourcing Pharma

Three leaders from pharma ingredients and innovation firm Lonza share views on challenges and opportunities likely to face the industry in coming months.

105
105
article thumbnail

The top 5 pharma M&A deals of 2020

pharmaphorum

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. That said, there were still some interesting moves indicating new directions of travel for big pharma players – with most deals focused on specific drugs from biotechs, particularly in cancer (though we did get rumours of an AstraZeneca-Gilead merger , which would have been the

article thumbnail

Green light for AZ’s Tagrisso in early-stage lung cancer

Pharma Times

EGFR-TKI approved in the US for early non-small cell lung cancer

57
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Benefits of Medical Software Company Products

Pharma Mirror

During the last couple of years, medical software has gained a lot of momentum. It’s crucial for monitoring the health of patients, and it’s one of the best ways to put human ingenuity to use. The market for this niche is getting bigger, and it’s going to cross 30 billion dollars soon. Managers and local clinics need to know about all the benefits of using these kinds of programs.

52
article thumbnail

Collaboration to chart AI-generated map of the immune system

Outsourcing Pharma

A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.

article thumbnail

5 ways digital health, and digital pharma, changed in 2020

pharmaphorum

Reviewing 2019’s key digital health stories last year I suggested that, while big strides continued to be made, any definitive ‘coming of age’ moment for the sector was unlikely. But that was before the first reports emerged of a highly contagious coronavirus and 2020 will be forever associated with COVID-19 and the global devastation and disruption it has wrought.

article thumbnail

Pfizer, BioNTech win EU authorisation for COVID-19 vaccine Comirnaty

Pharma Times

Follows positive opinion issued by EMA's CHMP

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Stephen Towers, PhD

Pharma Marketing Network

Stephen Towers, PhD is a leader in medical communications and healthcare marketing, with extensive experience in developing promotional medical education programs and medical affairs initiatives across numerous therapeutic areas and on behalf of diverse US healthcare organizations, from large pharmaceutical companies to smaller biotechs. As VP at Chameleon Communications (part of Omnicom Health Group), he leverages his scientific acumen and pharmaceutical expertise to create impactful scientific

article thumbnail

Supply chain woes can lead to billion-dollar problems: Cloudleaf

Outsourcing Pharma

A new survey from the supply-chain analysis company revals inefficiencies, inaccurate data and other flaws can be costly in terms of revenue, reputation and patient lives.

87
article thumbnail

Moderna and BioNTech – who are they?

pharmaphorum

Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. Just who are these companies and who is behind them, asks Richard Staines. A year ago, the names Moderna and BioNTech were known mainly to those who followed biotech and pharma dealings. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against t

Vaccines 111
article thumbnail

AMO Pharma launches late-stage study of CMD candidate

Pharma Times

REACH-CDM study was based on results of positive phase II data

52
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem

Pharma Marketing Network

Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. With over 100 late-stage gene therapy trials underway and an increasing number of gene-editing technologies entering trials, it’s clear that this trickle will soon become a torrent.

article thumbnail

Sanofi joins Aqemia to develop COVID-19 treatments

Outsourcing Pharma

The pharma firm will lend support to Aqemiaâs high-tech drug discovery tools in order to work on discovery and development of therapies for the virus.

64
article thumbnail

NICE backs AZ’s Forxiga for heart failure

pharmaphorum

Just a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE for this use by the NHS in England and Wales. Forxiga (dapagliflozin) – originally developed as a type 2 diabetes drug – is the first SGLT2 inhibitor to be approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without diabetes.

FDA 98
article thumbnail

Aimmune’s peanut allergy med Palforzia wins EU approval

Pharma Times

Drug becomes first treatment for peanut allergy in the EU

52
article thumbnail

Tiotropium Systemic Absorption – How Much?

Med Ed 101

I had this question the other day about the extent of tiotropium systemic absorption and I had to double-check. I knew that there was some, but wasn’t sure how prevalent it was. According to an older article, the tiotropium systemic absorption is approximately 20% (19.5% to be exact). The more important question is what does […]. The post Tiotropium Systemic Absorption – How Much?

40
article thumbnail

Clinical informatics company raises $21.5m to fund tech

Outsourcing Pharma

Ovation.io will harness the funding to develop software and data products supporting drug discovery and development, creating diagnostics and more.

52
article thumbnail

Servier beefs up in cancer, buying Agios’ oncology business for $1.8bn

pharmaphorum

French pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise in a deal that leaves the US biopharma focused on genetic disorders. It’s a major change of direction for Boston-based Agios, which has been concentrating on the oncology market since its inception in 2008, bringing the Bristol Myers Squibb-partnered Tibsovo (ivosidenib) for IDH1-mutant acute myeloid leukaemia to the US market.

article thumbnail

EU green light for Zogenix’s Fintepla

Pharma Times

Oral solution approved to treat seizures associated with Dravet syndrome

51
article thumbnail

My Top 5 Drugs That Cause Diarrhea

Med Ed 101

Diarrhea is a nuisance that can lead to non-adherence to drug therapy. In some cases, diarrhea can be even more than a nuisance and may risk the lives of our patients. Below, I outline my top 5 drugs that cause diarrhea. Metformin When considering drugs that cause diarrhea, I want to give you the most […]. The post My Top 5 Drugs That Cause Diarrhea appeared first on Med Ed 101.

40
article thumbnail

COVID-19 response platform expands reach across US

Outsourcing Pharma

The GoGetTested response operating system, to date used to administer more than 200,000 tests, now will scale to include health systems in more states.

52
article thumbnail

AZ’s Tagrisso gets new early lung cancer use in US

pharmaphorum

AstraZeneca’s Tagrisso (osimertinib) has been approved by the FDA in a new lung cancer indication that extends its use to a group of patients with early-stage disease. The new use covers adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after a potentially curative operation.

FDA 98
article thumbnail

Amgen files KRAS inhibitor sotorasib with EMA

Pharma Times

Submission supported by results from phase II CodeBreaK 100 study

48
article thumbnail

What’s Ahead in 2021?

Pharma Marketing Network

What will stay the same in 2021? “COVID accelerated our 5-year digital transformation plan into a 5-month plan”. That client comment was amazingly accurate. While initially we saw a great deal of uncertainty with clients all responding differently, by April clients were forming strategic plans to adapt. By July, an intense focus on digital emerged and the rest of 2020 has been a whirlwind of activity as budgets shifted toward digital.

article thumbnail

Biomarkers pave the way to personalized care: Quanterix

Outsourcing Pharma

An executive from the digital biomarker tech company explains the myriad benefits of biomarker analysis in advancing precision health solutions.

52
article thumbnail

2020 review – Pharma’s progress outside of COVID-19

pharmaphorum

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. But there was some considerable progress in other fields of medicine even though research efforts were diverted away, reports Richard Staines. The American Society of Clinical Oncology (ASCO) annual conference was one of the highlights of the year in cancer research and the fact it was held virtually did not distract from some stunni

FDA 96